Zim Laboratories reported a consolidated net loss of ₹4.02 crore for the quarter ended June 2026, representing a significant deterioration from the net loss of ₹1.87 crore recorded in the corresponding quarter of the previous financial year. According to reports from Business Standard, the company's financial performance showed mixed results with revenue growth offset by operational challenges.
The company demonstrated strong revenue growth with sales rising 31.24% to ₹94.18 crore in Q1 FY27 compared to ₹71.76 crore in the same quarter of the previous financial year. As reported by Business Standard, this substantial revenue increase indicates robust demand for the company's products or services during the quarter.
The company's operating profit margin (OPM) declined to 2.60% in Q1 FY27 from 5.94% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin compression reflects increased operational costs or pricing pressures that impacted the company's profitability despite the strong revenue growth.
PBDT (Profit Before Depreciation and Tax) turned negative at ₹0.20 crore in Q1 FY27 compared to a positive ₹2.43 crore in the previous year quarter. As reported by Business Standard, PBT (Profit Before Tax) declined 129% to ₹-5.57 crore from ₹-2.43 crore in the corresponding quarter of the previous year. These metrics indicate that the company faced operational challenges that impacted its bottom-line performance despite the strong top-line growth.
